Loading…
Loading…
EQUITY / NASDAQ · XNCM
NeuroOne Medical Technologies Corporation
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.12 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 1.12 USD · Volume 201,394
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 3 | 2025 / Quarter 3 | Change |
|---|---|---|---|
| Revenue | 1,973,105 USD | 1,696,050 USD | +16.34% |
| Operating profit | -2,424,312 USD | -1,886,600 USD | — |
| Net income | -2,006,331 USD | -1,500,868 USD | — |
| Cash and cash equivalents | 2,047,596 USD | — | — |
| Total liabilities | 2,418,552 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 304/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 210/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 309/30/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Year end10/01/2024 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 304/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 2,047,596 USD | — | — | — | — | 6,570,382 USD | 6,570,382 USD | — |
| Gross profitIncome statement | 1,182,609 USD | 3,740,701 USD | — | 2,558,092 USD | — | — | 5,141,406 USD | 914,835 USD |
| Net incomeIncome statement | -2,006,331 USD | -5,826,243 USD | -2,382,022 USD | -3,819,912 USD | -1,437,890 USD | — | -3,605,374 USD | -1,500,868 USD |
| Operating profitIncome statement | -2,424,312 USD | -6,528,816 USD | — | -4,104,504 USD | — | — | -4,226,473 USD | -1,886,600 USD |
| RevenueIncome statement | 1,973,105 USD | 6,727,790 USD | — | 4,754,685 USD | — | — | 9,097,692 USD | 1,696,050 USD |
| Total assetsBalance sheet | 6,186,095 USD | — | — | — | — | 10,785,647 USD | 10,785,647 USD | — |
| Total equityBalance sheet | 3,767,543 USD | — | 5,077,283 USD | — | 6,401,925 USD | 7,072,522 USD | 7,072,522 USD | 8,177,453 USD |
| Total liabilitiesBalance sheet | 2,418,552 USD | — | — | — | — | 3,713,125 USD | 3,713,125 USD | — |
| Capital expendituresCash flow statement | — | 98,929 USD | — | 79,270 USD | — | — | 81,742 USD | — |
| Financing cash flowCash flow statement | — | 1,102,478 USD | — | 757,445 USD | — | — | 8,029,354 USD | — |
| Investing cash flowCash flow statement | — | -98,929 USD | — | -79,270 USD | — | — | -81,742 USD | — |
| Operating cash flowCash flow statement | — | -5,526,335 USD | — | -4,444,546 USD | — | — | -2,837,272 USD | — |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 06/12/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 12/17/2025 | Open report ↗ Published: 08/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.